Today, PSI CRO, a full-service contract research organization, announced their expansion into South Africa.
South Africa is a multi-cultural nation with a population of ~50 million people. It has a long history of conducting clinical trials. As such, there exists a strong infrastructure to support all needed activities including regulatory oversight and experienced researchers. Data generated from South African trials receives international acceptance. Expert opinion leaders work in South Africa, providing a high standard of medical care. Therefore, patients who have received state-of-the-art therapy, in addition to treatment-naïve patients, may be recruited for clinical trials. PSI will expand its access to all African countries from the strong base in Pretoria. PSI’s current experience in South Africa stretches across the areas of oncology, CNS, urology, diabetes and other therapeutic areas.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.